Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy

• Published in: Translational stroke research Vol. 12; no. 3; pp. 416 - 427
• Main Authors: Jiang, Yinghua, Liu, Ning, Han, Jinrui, Li, Yadan, Spencer, Pierce, Vodovoz, Samuel J., Ning, Ming-Ming, Bix, Gregory, Katakam, Prasad V. G., Dumont, Aaron S., Wang, Xiaoying
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-06-2021; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Biomedicine; Cardiology; Cardiovascular disease; Diabetes; Diabetes Mellitus; Epidemiology; Fibrinolytic Agents - therapeutic use; Humans; Hyperglycemia; Hyperglycemia - complications; Hyperglycemia - drug therapy; Ischemia; Metabolism; Mortality; Neurology; Neurosciences; Neurosurgery; Patients; Plasma; Review Article; Risk factors; Stroke; Stroke - complications; Stroke - drug therapy; Thrombolytic Therapy; Tissue Plasminogen Activator - therapeutic use; Treatment Outcome; Vascular Surgery; Hyperglycemia; Ischemic stroke; Tissue-type plasminogen activator; Diabetes mellitus; Intracerebral hemorrhage; Recanalization rate
• ISSN: 1868-4483; 1868-601X
• DOI: 10.1007/s12975-020-00872-3

Intravenous administration of tissue-type plasminogen activator (IV tPA) therapy has long been considered a mainstay in ischemic stroke management. However, patients respond to IV tPA therapy unequally with some subsets of patients having worsened outcomes after treatment. In particular, diabetes mellitus (DM) is recognized as a clinically important vascular comorbidity that leads to lower recanalization rates and increased risks of hemorrhagic transformation (HT). In this short-review, we summarize the recent advances in understanding of the underlying mechanisms involved in post-IV tPA worsening of outcome in diabetic stroke. Potential pathologic factors that are related to the suboptimal tPA recanalization in diabetic stroke include higher plasma plasminogen activator inhibitor (PAI)-1 level, diabetic atherogenic vascular damage, glycation of the tPA receptor annexin A2, and alterations in fibrin clot density. While factors contributing to the exacerbation of HT in diabetic stroke include hyperglycemia, vascular oxidative stress, and inflammation, tPA neurovascular toxicity and imbalance in extracellular proteolysis are discussed. Besides, impaired collaterals in DM also compromise the efficacy of IV tPA therapy. Additionally, several tPA combination approaches developed from experimental studies that may help to optimize IV tPA therapy are also briefly summarized. In summary, more research efforts are needed to improve the safety and efficacy of IV tPA therapy in ischemic stroke patients with DM/poststroke hyperglycemia.